Application of medication composition of containing extractive of astragalus root in preparing medicine for treating insufficiency of blood supply for brain

Abstract

An application of the medicinal composition composed of astragalus root and anemarrhena rhizome in preparing the medicines for treating chronic cerebral ischemia is disclosed.

Description

Technical field [0001] The invention belongs to the field of medicine, and specifically relates to the application of a pharmaceutical composition containing an astragalus extract in the preparation of a medicine for treating chronic cerebral insufficiency. Background technique [0002] Origin of the concept [0003] Chronic Cerebral Circulation Inefficiency (CCCI) refers to a state where the blood supply to the whole brain is reduced (less than 40-60ml / 100g brain tissue / minute), rather than focal cerebral ischemia. It is a relatively new disease name proposed in the first 10 years abroad. Clinically, there are often elderly or pre-elderly patients who repeatedly complain of conscious symptoms such as heavy head and dizziness. Except for fundus arteriosclerosis, they have neither focal signs of nerve damage nor abnormal brain CT. These patients are often diagnosed as "brain Arteriosclerosis". As we all know, the concept and clinical diagnostic crite...

AI Technical Summary

Problems solved by technology

[0033] 3. No focal neurological signs of the brain

[0043] 3. No focal neurological signs of the brain;

[0044] 4. CT\MRI without vascular organic brain changes;

[0056] At present, the drugs used clinically to treat CCCI include: THA: cholinesterase inhibitor, GST-21: central N-choline receptor inhibitor, FK506: immunosuppressant, Nimsuperzine: Cox-2 inhibitor, etc. A good short-term clinical effect has been achieved, but the long-term effect needs further study